⁃ Both male and female participants are eligible for study evaluation. There are no exclusions for any racial/ethnic groups. Efforts will be made to extend accrual to a representative population. In order to be eligible to participate in this study, an individual must meet all of the following criteria:

• Provision of signed and dated informed consent form.

• Ability of subject to understand and the willingness to sign a written informed consent document.

• Must be able to read, write, understand, and complete English-language study-related forms and adequately communicate in English.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Male or female, aged 18 and older.

• In good general health as evidenced by medical history.

• Diagnosed with one painful Morton s neuroma in the index foot

• Has not attained satisfactory pain relief with conservative, oral analgesic and at least one kind of injection treatment for Morton s neuroma.

• Exhibits moderate to severe foot pain due to the Morton s neuroma (average worst pain \>= 5 on the 0-10 numeric pain rating scale NRS) as assessed verbally at \>= 3 individual days during prescreening.

• For females of reproductive potential who are sexually active: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional one (1) month after administration of RTX.

⁃ If a female, be sterile (surgically or biologically) \* or at least one year postmenopausal\*\*, or have a monogamous partner who is surgically sterile, or have a same sex partner, or if in a heterosexual relationship, must agree to do the following for at least one month after receiving investigational product (IP):

• Practice abstinence, or

• Use at least one of the following medically acceptable methods of birth control:

‣ Hormonal methods such as oral, implantable, injectable, vaginal ring, or transdermal contraceptives (must have started a minimum of 1 full cycle, based on the subject s usual menstrual cycle period, before IP dose

⁃ Intrauterine device

⁃ Double-barrier method (condoms, sponge, or diaphragm with spermicidal jellies or cream).

∙ Defined as having had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or bilateral tubal ligation/occlusion at least 6 weeks prior to screening; or having a congenital or acquired condition that prevents childbearing

• Defined as at least 12 months with no menses without an alternative medical cause) \[can be confirmed with follicle stimulating hormone level (FSH) in the post-menopausal range (FSH levels \>=40 milli international units/mL (mIU/mL) at Screening) if the subject is not on hormonal replacement therapy\]

• For males of reproductive potential who are sexually active: use of condoms or other methods to ensure effective contraception with partner for one (1) month after administration of (RTX).

⁃ If a male of reproductive potential, unless he has a same sex partner or a partner who is sterile or at least one year post-menopausal, must agree to do the following for at least one month after receiving IP

• practice abstinence from heterosexual activity or

• use (or have their partner use) acceptable contraception (see criterion above) during heterosexual activity

⁃ Male study participants should not donate sperm for 3 months after RTX injection.